AllisWell Bio Builds the Future of Drug Screening with Integrated 3D Cell Culture and Bioprinting
Exhibitor: ALLISWELL BIO CO., LTD.
Date: 2025-06-09
Booth No.: L223
As the demand for cell therapy, drug development, and personalized medicine continues to rise, constructing physiologically relevant in vitro systems has become a critical focus in both research and industry. With the U.S. FDA announcing the gradual removal of mandatory animal testing for biologics development, the spotlight has shifted toward advanced cell-based and in vitro models for preclinical studies. In this transition, 3D cell culture and high-fidelity tissue models are rapidly replacing traditional 2D cultures and animal models.
To support this paradigm shift, AllisWell Bio integrates solutions across 3D culture, bioprinting, microenvironment simulation, and drug screening—bridging early-stage experiment design, process scale-up, and clinical translation. This comprehensive approach empowers researchers to adopt more accurate, controllable, and standardized in vitro platforms for the future of biomedical research.
Official Link: FDA Announcement
From Flat to Spherical: The Evolution of 3D Cell Culture
To overcome the limitations of traditional 2D adherent culture in terms of cell morphology and function, AllisWell Bio offers a range of 3D cell culture technologies that more accurately replicate the in vivo microenvironment. Tantti®'s SpherTantrix scaffold, made from non-animal-derived materials, features a microporous structure with orderly alignment, enabling consistent spheroid formation (~100–120 μm) within 2–3 days. The platform is highly reproducible and ideal for preclinical drug screening, tumor modeling, and cancer research. Its high optical clarity and low background fluorescence facilitate imaging and analysis, making it compatible with high-throughput systems.
In combination with FDCell’s ultra-low attachment plates and Collagen Solution’s soluble collagen, the system supports the formation of physiologically relevant 3D structures, enhancing functional performance and predictive drug response. These tools are widely applied in oncology, regenerative medicine, and toxicology research.
Precision Microtissue Engineering with Evolving 3D Bioprinting Platforms
Accurately mimicking tissue microstructures is vital for advanced drug development and personalized medicine. The CLECELL 3D bioprinting platform—ACTIVO—distributed by AllisWell Bio, delivers an all-in-one solution for both academic and industrial users. With five-axis pathing and multi-material, multi-nozzle support, ACTIVO enables the construction of layered 3D models with heterogeneous cell compositions. Its triple-zone temperature control system ensures optimal performance for cell printing, bioink development, and pseudo-tissue fabrication.
By using CLECELL’s proprietary elastic collagen hydrogels and thermo-responsive support gels, the platform enables applications such as tumor microenvironment reconstruction, drug delivery system prototyping, and composite tissue printing—bridging early-stage research and clinical applications.
Enhanced Physiological Simulation for Predictive In Vitro Systems
To improve physiological relevance and predictive accuracy of 3D cell models, AllisWell Bio offers a series of artificial biological fluids from TMA Lab. These fluids simulate various organ environments, including cerebrospinal fluid (CSF), bronchoalveolar lavage (BAL), synovial fluid (SF), and gastric fluids. Formulated to match human physiological conditions—chemical composition, osmotic pressure, and customizable pH or ion concentrations—these biomimetic fluids support specific cellular functions while minimizing interference from traditional culture media.
When combined with 3D culture and bioprinting systems, these fluids enhance the reproducibility of cellular responses and stability of platforms, offering reliable outcomes in drug efficacy, mechanism studies, and toxicity prediction. This positions them as essential components in animal-free experimental strategies.
Automated Cell Culture for Stability and Efficiency
To meet the demand for robust and reproducible cell culture, AllisWell Bio introduces the MakCell™ benchtop automated cell culture system from Japan’s J-TEC. Designed for efficiency and contamination control, MakCell™ features automated media exchange, HEPA-filtered sterile environments, auto-cleaning functions, and supports a variety of culture vessels. With hypoxic culture settings and multi-media switching capabilities, it is ideal for sensitive cell types such as iPSCs, MSCs, and 3D spheroids.
When integrated with Tantti® SpherTantrix, FD Cell cultureware, and the ACTIVO 3D bioprinter, MakCell™ supports the creation of multi-cellular 3D models, providing an end-to-end workflow from cell handling to drug response evaluation.
AllisWell Bio — Your Trusted Partner in Biomedical Innovation
AllisWell Bio is committed to sourcing and integrating cutting-edge life science technologies from around the world. From cell culture to 3D bioprinting, biomimetic environments, and precision drug screening, AllisWell Bio delivers full-spectrum solutions to accelerate biomedical R&D in Taiwan and across Asia. With deep technical expertise and excellent service, AllisWell Bio supports the advancement of new drug development and regenerative medicine—empowering the industry to thrive on the global stage.
More Exhibitor's Press Release
- Honya Medical Strengthens Local Presence and Expands Toward Global Clinical Excellence HONYA MEDICAL CO., LTD. / 2025-07-30
- Honya’s MiSaver: A New Frontier in Treating Heart Damage After Heart Attacks HONYA MEDICAL CO., LTD. / 2025-07-30
- Link-Best debuted at BIO Asia Exhibition. Products attracted attention and Ignited Spark. LINK-BEST BIOSCIENCE CO., LTD. / 2025-07-30
- GoldenBiotech-Advancing First-line treatment of Meta. PanCa GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- GlobalBio: 國鼎生技-開發Antroquinonol 造福抗癌研究治療 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- GoldenBiotech Seminar:Advancing First-Line Therapy for Metastatic Pancreatic Cancer: Global Phase 3 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- AAVnerGene and TFBS Bioscience Announce Collaboration to Develop Innovative AAV Technology Platform TFBS BIOSCIENCE, INC. / 2025-07-25
- Visit Us at BIO Asia–Taiwan 2025! July 24 – July 27 GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-25
- GBC CellBio™ a2000 has been recognized with a 2025 Edison Award. GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-24
- GBC AI Biotech Building Officially Commissioned. GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-24
- Your Invitation to Innovation – Booth M412 Forum MAJOR SCIENCE CO.,LTD / 2025-07-24
- Ecotek Engineering Corp.: Your Integrated Partner for Biopharma Facility and Process Equipment Solut MAJOR SCIENCE CO.,LTD / 2025-07-24
- About major science - Create life sciences research instruments through quality and innovation MAJOR SCIENCE CO.,LTD / 2025-07-24
- IOT無線連續監測系統 - 廠房、倉儲、實驗室 溫、濕度測繪 XIN TOP CORPORATION / 2025-07-24
- MarkerX Unveils MyeloTrak™ at BIO Asia, Redefining Multiple Myeloma Management with Non-invasive, Pr MARKER X CO., LTD. / 2025-07-23
- CancerFree Biotech Selected for OIST Startup Accelerator Program CANCERFREE BIOTECH LTD. / 2025-07-23
- AI Sparks a New Wave in Cancer Research: How a Taiwanese Startup Is Breaking Lab Bottlenecks and Ad CANCERFREE BIOTECH LTD. / 2025-07-23
- Transin Biomedical showcases the innovative strength of smart medical devices TRANSIN BIOMEDICAL CO., LTD. / 2025-07-23
- TaiMed Biologics Hosts Interactive Activities at BIO Asia 2025 to Promote HIV Awareness TAIMED BIOLOGICS INC. / 2025-07-22
- A Pioneer for Over Two Decades, Cell-Bio Biotechnology to Showcase Comprehensive Solutions at BioAsi CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-22